Back to Results

Telomir Pharmaceuticals Inc (TELO)

Telomir Pharmaceuticals Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics aimed at upstream biological mechanisms associated with aging and age-related diseases. Its lead program, Telomir-1, is an oral small-molecule metal ion regulator being studied for potential use in conditions such as Wilson’s disease, type 2 diabetes, age-related macular degeneration, oncology, epigenetic regulation, Alzheimer’s disease, and Progeria. The company was incorporated in 2021 and is headquartered in Miami, Florida. It operated previously under the name Metallo Therapies Inc., adopting its current name in October 2022.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-TELO
$0.89
-20.9% Downside
Overvalued
$15.50 1,271.7% Upside
—
Bargain
Weak
—
—
—
0.0%
September 2, 2026
-6.9x
12.7x
—
63.218 M
58.205 M
0.9%
69.1%
31.4
—
49.9%
Send a message
Valuation • Fair Value

Telomir Pharmaceuticals Inc (NASDAQ-TELO) Fair Value by Valuation Model

Compare the primary fair value estimate for Telomir Pharmaceuticals Inc (NASDAQ-TELO) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.89

Estimated downside of 20.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.50

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.29

Comparable-company valuation reference.

Analyst Price Target

$15.50 1,271.7% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Telomir Pharmaceuticals Inc (NASDAQ-TELO) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Telomir Pharmaceuticals Inc (NASDAQ-TELO)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

1.5 M

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Telomir Pharmaceuticals Inc (NASDAQ-TELO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Telomir Pharmaceuticals Inc (NASDAQ-TELO)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

31.4

Relatively strong balance-sheet zone.

FCF / Net Income

49.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Telomir Pharmaceuticals Inc (NASDAQ-TELO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Telomir Pharmaceuticals Inc (NASDAQ-TELO)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 2, 2026

Days to Earnings

43

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Telomir Pharmaceuticals Inc (NASDAQ-TELO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Telomir Pharmaceuticals Inc (NASDAQ-TELO) Stock Forecast & Technical Outlook

Review Telomir Pharmaceuticals Inc (NASDAQ-TELO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Telomir Pharmaceuticals Inc (NASDAQ-TELO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Telomir Pharmaceuticals Inc (NASDAQ-TELO) Stock FAQ

Quick answers about Telomir Pharmaceuticals Inc (NASDAQ-TELO) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.89
Estimated downside 20.9%
Valuation Rating
Overvalued
Estimated downside of 20.9%
Analyst Target
$15.50 1,271.7% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is $0.89. This implies an estimated downside of 20.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 20.9% versus the current market price.

The available analyst price target for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is $15.50 1,271.7% Upside.

The current financial health read for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is September 2, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Telomir Pharmaceuticals Inc (NASDAQ-TELO) is -6.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Telomir Pharmaceuticals Inc is 63.218 M.

The current enterprise value listed for Telomir Pharmaceuticals Inc is 58.205 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Telomir Pharmaceuticals Inc is NASDAQ-TELO, and the stock is listed on NASDAQ.

Telomir Pharmaceuticals Inc (NASDAQ-TELO) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Telomir Pharmaceuticals Inc is 0.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Telomir Pharmaceuticals Inc is 69.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NASDAQ View more

AstraZeneca PLC ADR (AZN) AstraZeneca PLC ADR (AZN)
Sanofi ADR (SNY) Sanofi ADR (SNY)
Royalty Pharma Plc (RPRX) Royalty Pharma Plc (RPRX)
Viatris Inc (VTRS) Viatris Inc (VTRS)
Jazz Pharmaceuticals PLC (JAZZ) Jazz Pharmaceuticals PLC (JAZZ)
Axsome Therapeutics Inc (AXSM) Axsome Therapeutics Inc (AXSM)
Corcept Therapeutics Incorporated (CORT) Corcept Therapeutics Incorporated (CORT)
Crinetics Pharmaceuticals Inc (CRNX) Crinetics Pharmaceuticals Inc (CRNX)
Liquidia Technologies Inc (LQDA) Liquidia Technologies Inc (LQDA)
Belite Bio Inc ADR (BLTE) Belite Bio Inc ADR (BLTE)
Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Incorporated (LGND)
Definium Therapeutics Inc (DFTX) Definium Therapeutics Inc (DFTX)
Amneal Pharmaceuticals Inc Class A (AMRX) Amneal Pharmaceuticals Inc Class A (AMRX)
Indivior PLC (INDV) Indivior PLC (INDV)
Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX)
Enliven Therapeutics Inc (ELVN) Enliven Therapeutics Inc (ELVN)
Alumis Inc (ALMS) Alumis Inc (ALMS)
Structure Therapeutics Inc ADR (GPCR) Structure Therapeutics Inc ADR (GPCR)
MBX Biosciences Inc (MBX) MBX Biosciences Inc (MBX)
Supernus Pharmaceuticals Inc (SUPN) Supernus Pharmaceuticals Inc (SUPN)
ATAI Beckley Inc (ATAI) ATAI Beckley Inc (ATAI)
Regencell Bioscience Holdings Ltd (RGC) Regencell Bioscience Holdings Ltd (RGC)
Tarsus Pharmaceuticals Inc (TARS) Tarsus Pharmaceuticals Inc (TARS)
Trevi Therapeutics Inc (TRVI) Trevi Therapeutics Inc (TRVI)